Literature DB >> 14746507

Toward Alzheimer therapies based on genetic knowledge.

John Hardy1.   

Abstract

Genetic analysis has allowed the dissection of the pathogenic pathway that leads to Alzheimer's disease. It has also been integral to the development of earlier and more accurate diagnostic practices. This analysis has identified many potential therapeutic targets, and clinical trials aimed at these targets are now under way. If these approaches are successful, it will be a spectacular validation of genetic-knowledge-based treatment strategies; if they are not, researchers will need to re-evaluate this approach toward understanding and developing strategies for treating complex diseases.

Entities:  

Mesh:

Year:  2004        PMID: 14746507     DOI: 10.1146/annurev.med.55.091902.103607

Source DB:  PubMed          Journal:  Annu Rev Med        ISSN: 0066-4219            Impact factor:   13.739


  9 in total

Review 1.  Disease-modifying therapies in Alzheimer's disease: how far have we come?

Authors:  Michael Hüll; Mathias Berger; Michael Heneka
Journal:  Drugs       Date:  2006       Impact factor: 9.546

2.  Neuroimaging: anything to do with neurotherapeutics?

Authors:  Jose C Masdeu; Rohit Bakshi
Journal:  NeuroRx       Date:  2005-04

3.  Beta-amyloid toxicity in embryonic rat astrocytes.

Authors:  Poincyane Assis-Nascimento; Karen M Jarvis; Jeremy R Montague; Laura M Mudd
Journal:  Neurochem Res       Date:  2007-04-04       Impact factor: 3.996

4.  Amyloid-beta protein clearance and degradation (ABCD) pathways and their role in Alzheimer's disease.

Authors:  Robert J Baranello; Krishna L Bharani; Vasudevaraju Padmaraju; Nipun Chopra; Debomoy K Lahiri; Nigel H Greig; Miguel A Pappolla; Kumar Sambamurti
Journal:  Curr Alzheimer Res       Date:  2015       Impact factor: 3.498

Review 5.  Expression of Linear and Circular lncRNAs in Alzheimer's Disease.

Authors:  Soudeh Ghafouri-Fard; Mohammadreza Safari; Mohammad Taheri; Mohammad Samadian
Journal:  J Mol Neurosci       Date:  2021-08-20       Impact factor: 3.444

6.  17β-Estradiol regulates insulin-degrading enzyme expression via an ERβ/PI3-K pathway in hippocampus: relevance to Alzheimer's prevention.

Authors:  Liqin Zhao; Jia Yao; Zisu Mao; Shuhua Chen; Yan Wang; Roberta Diaz Brinton
Journal:  Neurobiol Aging       Date:  2010-01-06       Impact factor: 4.673

7.  Beta-amyloid toxicity and reversal in embryonic rat septal neurons.

Authors:  Karen Jarvis; Poincyane Assis-Nascimento; Laura M Mudd; Jeremy R Montague
Journal:  Neurosci Lett       Date:  2007-08-09       Impact factor: 3.046

8.  Prophylactic treatment with paroxetine ameliorates behavioral deficits and retards the development of amyloid and tau pathologies in 3xTgAD mice.

Authors:  Rhonda L Nelson; Zhihong Guo; Veerendra Madala Halagappa; Michelle Pearson; Audrey J Gray; Yasuji Matsuoka; Martin Brown; Bronwen Martin; Titilola Iyun; Stuart Maudsley; Robert F Clark; Mark P Mattson
Journal:  Exp Neurol       Date:  2007-02-13       Impact factor: 5.330

9.  Modulating innate immune activation states impacts the efficacy of specific Aβ immunotherapy.

Authors:  Yona Levites; Cory Funk; Xue Wang; Paramita Chakrabarty; Karen N McFarland; Baxter Bramblett; Veronica O'Neal; Xufei Liu; Thomas Ladd; Max Robinson; Mariet Allen; Minerva M Carrasquillo; Dennis Dickson; Pedro Cruz; Danny Ryu; Hong-Dong Li; Nathan D Price; NIlüfer Ertekin-Taner; Todd E Golde
Journal:  Mol Neurodegener       Date:  2021-05-06       Impact factor: 18.879

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.